# Repair Impact Fund

> Repair Impact Fund is a VC fund in Hellerup backing Biotechnology and Health Care. See 12 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Hellerup, Denmark
- Total investments: 12
- Last investment: Feb 2024
- Lead investor: 67%
- Last updated: Aug 2026
- Website: https://www.repair-impact-fund.com

Repair Impact Fund is a VC fund in Hellerup focused on Biotechnology and Health Care. Novo Holdings established the REPAIR Impact Fund commissioned by the Novo Nordisk Foundation in February 2018 to invest in companies involved in discovering and the early-stage development of therapies targeting resistant microorganisms.REPAIR is an acronym: Replenishing and Enabling the Pipeline for Anti-Infective Resistance.The Novo NordiskFoundation is commissioning the initiative, and Novo Holdings is executing it.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 7 | 58% |
| Health Care | 3 | 25% |
| Therapeutics | 2 | 17% |
| Pharmaceutical | 2 | 17% |
| Medical | 1 | 8% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 4 | 33% |
| Series A | 2 | 17% |
| Series B | 2 | 17% |
| Grant | 1 | 8% |
| Series C | 1 | 8% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 17% |
| France | 1 | 8% |
| Denmark | 1 | 8% |
| Switzerland | 1 | 8% |
| United Kingdom | 1 | 8% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| LimmaTech Biologics | LimmaTech Biologics AG is a clinical-stage biopharmaceutical company. | $3M | Series A | Feb 01, 2024 |  |
| Revagenix | Revagenix is a biopharmaceutical company discovering and developing therapies to address medical needs. |  | Series B | Jan 05, 2024 |  |
| Revagenix | Revagenix is a biopharmaceutical company discovering and developing therapies to address medical needs. |  | Series B | Jan 05, 2024 |  |
| LimmaTech Biologics | LimmaTech Biologics AG is a clinical-stage biopharmaceutical company. | $36.5M | Series A | Oct 09, 2023 |  |
| Minervax | Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains. | $23.4M | Series C | Dec 15, 2022 |  |
| Minervax | Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains. | $52M | Series B | Dec 15, 2020 |  |
| Revagenix | Revagenix is a biopharmaceutical company discovering and developing therapies to address medical needs. | $4M | Series A | Jan 01, 2020 |  |
| Procarta Biosystems | Procarta Biosystems Ltd., established in 2007 by the scientific founders, Dr. Michael McArthur and Professor Mervyn Bibb, is a spin-out company from the John Innes Centre, Norwich, a world renowned scientific centre of excellence in plant science and microbiology. The company was initially established through Plant Bioscience Ltd (PBL), theinternationally regarded group specialising in early stage technology investment and IP management, on behalf of the JIC, the Sainsbury Laboratory and the Biotechnology and Biological Sciences Research Council.Procarta received seed funding in 2008 from the Rainbow and Iceni Seedcorn Funds and is currently headquartered on the Norwich Research Park. | $1.6M |  | Mar 05, 2019 |  |
| Minervax | Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains. | $4.8M | Grant | Jan 21, 2019 |  |
| IBT Vaccines | IBT Vaccines is a biotechnology company. | $3.9M |  |  |  |

10 of 12 investments shown.

## Co-investors
- [Tenmile](https://shizune.co/investors/profile/tenmile) — VC Fund, 5 deals together
- [Adjuvant Capital](https://shizune.co/investors/profile/adjuvant-capital) — VC Fund, 4 deals together
- [Sunstone Life Science Ventures](https://shizune.co/investors/profile/sunstone-capital-life-science) — VC Fund, 3 deals together
- [AXA Investment Managers](https://shizune.co/investors/profile/axa-investment-managers) — VC Fund, 2 deals together
- [Industrifonden](https://shizune.co/investors/profile/industrifonden) — VC Fund, 2 deals together
- [Novo Holdings](https://shizune.co/investors/profile/novo-a-s) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

## FAQ

### What does Repair Impact Fund invest in?

Repair Impact Fund invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Funding Round and Series A stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Repair Impact Fund last invest?

The most recent investment recorded for Repair Impact Fund closed in Feb 2024. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co